World’s Largest Real-World Analysis of RESET® Confirms Substantial and Durable Benefits for Obesity and Type 2 Diabetes
Data from 1,298 patients shows nearly 19% weight loss, meaningful blood sugar reduction, and evidence that nine months of treatment achieves the same benefits with fewer complications
London, 8 September 2025 – Morphic Medical, creator of RESET® – the first incision-free, endoscopic device designed to target the underlying cause of obesity and type 2 diabetes – today announces that new data from the world’s largest registry of RESET patients will be presented at the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) 2025 World Congress in Santiago, Chile, the annual gathering of obesity experts. The presentation will be delivered by Professor Ricardo Cohen, President of IFSO.
The new data comes from a global registry capturing real-world outcomes in 1,298 patients treated with RESET across 37 centres in 12 countries, including NHS hospitals in Birmingham, London, Southampton, Manchester and Glasgow. It represents the most comprehensive analysis of RESET in routine clinical practice to date.
The findings confirm that RESET delivers substantial and durable benefits:
- Patients lost an average of 18.9% of their total body weight
- Blood sugar levels – as measured by HbA1c, the standard test for long-term glucose control – fell by 1.3 percentage points, with the greatest improvements seen in patients starting at higher levels
- Benefits were durable, with 77% of patients maintaining improvement three years after RESET was removed
- The new research-driven, nine-month treatment approach delivers all of the benefits of weight loss and reduction in blood sugar, with fewer complications than the 12 month approach
RESET recently received CE (Conformité Européenne) Mark approval, ensuring it has met all European Commission safety, health and environmental protection requirements. The certification enables commercial launch in the European Union and other geographies that recognise CE marking, with rollout beginning in Germany and UK approval expected soon.
RESET has also been endorsed in the latest clinical guidelines for obesity treatment by both the European Society for Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE) – a strong validation from the medical community.
Mike Gutteridge, President & Chief Executive Officer of Morphic Medical, commented: “I am delighted by these results, which show that RESET delivers nearly 19% weight loss and meaningful improvements in blood sugar control. Unlike drug-based therapies, these benefits have been shown to last for years even after treatment has ended. With outcomes achieved in just nine months and with fewer risks, RESET is becoming an increasingly important option for people living with obesity and type 2 diabetes, as well as for governments worldwide tackling these global epidemics.”
Professor Ricardo Cohen, President of IFSO, commented: “This comprehensive analysis provides crucial evidence for optimizing RESET treatment protocols. The data will inform clinical guidelines and help practitioners worldwide deliver more effective, safer care to patients with obesity and type 2 diabetes. It represents a significant step forward in evidence-based endoscopic therapy.”
Dr Bob Ryder, Consultant Diabetologist at the Sandwell and West Birmingham NHS Trust, commented: “RESET is a 60cm impermeable sleeve implanted into the first part of the small intestine. It mimics some of the physiological effects of gastric bypass surgery without any surgery being required – boosting GLP-1, reducing insulin resistance and improving blood sugar and weight control. It offers a less-invasive option for people with type 2 diabetes and obesity who haven’t responded sufficiently to medications. The data presented at the IFSO meeting from the worldwide registry suggests that 9 months is the optimum time to leave RESET before it is removed again with an endoscopy procedure.”
[ENDS]
ABOUT MORPHIC MEDICAL
Morphic Medical is the developer of RESET®, the first incision-free, endoscopically delivered therapy designed to treat obesity and related metabolic disorders such as type 2 diabetes.
RESET is a duodenal-jejunal bypass liner (DJBL) that is implanted and removed endoscopically, remaining in place for up to nine months. By creating a temporary barrier in the upper intestine, it has been shown to support significant weight loss and improved blood sugar control by enhancing natural gut hormone responses, in a way similar to GLP1 therapies. Unlike gastric bypass surgery, RESET is minimally invasive and fully reversible.
RESET addresses a major global health need, with an estimated 93 million adults in Europe alone living with obesity and type 2 diabetes. Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts. For more information, please visit morphicmedical.com or follow us on X (formerly Twitter) and / or LinkedIn.
ABOUT IFSO
The International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) is a scientific organisation that brings together surgeons and health professionals involved in the treatment of severe obesity. It has 76 official member societies, as well as individual members from countries that have not yet formed a national association.
One of IFSO’s main activities is its annual World Congress, which provides a forum to exchange knowledge on surgical treatment of severe obesity, to present new techniques, research and concepts, and to connect with experts in the field. IFSO has also produced a number of guidelines and statements on severe obesity and its treatment, and is committed to the creation of a system for accreditation of individual surgeons and bariatric centres worldwide. Its main goal is the optimisation of the treatment of patients affected by severe obesity.